PEAR Therapeutics To Collaborate With Novartis To Develop Prescription Digital Therapeutics

PEAR Therapeutics (PEAR) recently announced it will be partnering with Novartis to develop prescription digital therapeutics for the treatment of schizophrenia and multiple sclerosis (MS). Novartis will offer its expertise in neurological disorder, clinical development, and commercialization.

Together the two companies will seek the approval for PEAR’s THRIVE digital therapeutic, a clinically validated prescription digital therapeutic that applies evidence-based, multi-modal, and reinforcement therapy. It is comprised of a user-facing smartphone application and clinician-facing web interface. PEAR and Novartis will also focus on developing a therapeutic application that alleviates disease burden in individuals with MS.

Prescription . . .